Home > Compound List > Product Information
VU0357121_Molecular_structure_CAS_433967-28-3)
Click picture or here to close

VU0357121

Catalog No. SML0019 Name Sigma Aldrich
CAS Number 433967-28-3 Website http://www.sigmaaldrich.com
M. F. C17H17F2NO2 Telephone 1-800-521-8956
M. W. 305.3191864 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 154942

SYNONYMS

IUPAC name
4-butoxy-N-(2,4-difluorophenyl)benzamide
IUPAC Traditional name
4-butoxy-N-(2,4-difluorophenyl)benzamide
Synonyms
VU0357121
4-Butoxy-N-(2,4-difluorophenyl)-benzamide

DATABASE IDS

CAS Number 433967-28-3
MDL Number MFCD03243692

PROPERTIES

Empirical Formula (Hill Notation) C17H17F2NO2
Purity ≥98% (HPLC)
Apperance powder
Solubility DMSO: ≥18 mg/mL
GHS Pictograms GHS09
GHS Signal Word Warning
GHS Hazard statements H410
European Hazard Symbols Nature polluting Nature polluting (N)
MSDS Link Download
GHS Precautionary statements P273-P501
Risk Statements 50/53
Safety Statements 60-61
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
VU0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax. Its site of action is distinct from the classical mGlu5 negative allosteric modulator (NAM) MPEP allosteric site or the site of a recetly discovered PAM, CPPHA. However, VU0357121shares a functional interaction with the MPEP site. VU0357121 is highly selective for activation of mGlu5 and is inactive or very weakly antagonizing at other mGlu receptor subtypes.
Description (简体中文)
Biochem/physiol Actions
VU0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax. Its site of action is distinct from the classical mGlu5 negative allosteric modulator (NAM) MPEP allosteric site or the site of a recetly discovered PAM, CPPHA. However, VU0357121shares a functional interaction with the MPEP site. VU0357121 is highly selective for activation of mGlu5 and is inactive or very weakly antagonizing at other mGlu receptor subtypes.

REFERENCES